铝佐剂灭活脊髓灰质炎疫苗IPV-Al在2、4、6及15-18月龄儿童中接种的免疫原性与安全性
这项在巴拿马开展的3期观察者盲法随机临床试验显示,2、4、6月龄婴儿接种IPV-Al(n=400)或标准IPV(n=400)后,IPV-Al对三个脊髓灰质炎病毒血清型的血清转化率均非劣于标准IPV;15-18月龄加强接种IPV-Al后,无论基础免疫使用何种疫苗,均表现出稳健的加强应答,且两种疫苗耐受性良好。
要点
- IPV-Al对三个血清型的血清转化率均非劣于标准IPV(95%CI下限均高于预设-10%点)。
- 基础免疫后血清转化率:IPV-Al组96.1% vs IPV组100%(1型);两组均100%(2型);IPV-Al组99.2% vs IPV组100%(3型)。
- 加强接种后GMT比值:IPV-Al基础组25.3 vs IPV基础组9.2(1型)、19.1 vs 6.5(2型)、50.4 vs 12.5(3型)。
核心结论
- IPV-Al在2、4、6月龄接种后对三个脊髓灰质炎病毒血清型的血清转化均非劣于标准IPV。
- 无论基础免疫接种何种疫苗,接种IPV-Al后均表现出稳健的加强应答,两种疫苗耐受性良好。
研究设计与样本
- 3期、观察者盲法、随机临床试验,在巴拿马开展。
- 婴儿在2、4、6月龄接种IPV-Al(n=400)或标准IPV(n=400)。
- 加强试验中受试者在15-18月龄接种单剂IPV-Al。
- 主要终点为基础免疫系列后1个月型特异性血清转化(抗体滴度≥4倍于估计母体抗体滴度且≥8);加强试验主要终点为型特异性加强效应(加强后第28天GMT/加强前第0天GMT)。
主要发现
- 基础免疫后血清转化率:IPV-Al组96.1% vs IPV组100%(1型);两组均100%(2型);IPV-Al组99.2% vs IPV组100%(3型)。
- 治疗差异的95%CI下限均高于预设-10%点:1型3.94%(-6.51; -2.01);2型0.0%(-1.30; -1.37);3型-0.85(-2.46; 0.40)。
- 加强效应(IPV-Al基础组 vs IPV基础组):1型25.3 vs 9.2;2型19.1 vs 6.5;3型50.4 vs 12.5。
- IPV-Al的安全性特征与IPV相当。
关键数值与推荐
- 非劣效界值为预设-10%点,三个血清型的治疗差异95%CI下限均高于该界值。
- 血清转化定义为抗体滴度≥4倍于估计母体抗体滴度且≥8。
- 加强效应定义为加强后第28天GMT/加强前第0天GMT。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Availability of affordable inactivated polio vaccines (IPV) is of major importance to meet the increasing global supply needs. The results presented here demonstrate non-inferiority of a reduced-dose, aluminium hydroxide-adjuvanted IPV (IPV-Al) to standard IPV. METHODS: A phase 3, observer-blinded, randomised, clinical trial was conducted in Panama in infants who received either IPV-Al (n = 400) or standard IPV (n = 400) at age 2, 4 and 6 months. In the booster trial, subjects received a single dose of IPV-Al at age 15-18 months. The primary endpoint was type-specific seroconversion, defined as an antibody titre ≥4-fold higher than the estimated maternal antibody titre and a titre ≥8, one month after the primary vaccination series. In the booster trial, the primary endpoint was the type-specific booster effects (geometric mean titre (GMT) post-booster (Day 28)/GMT pre-booster (Day 0). RESULTS: Seroconversion rates following primary vaccination with IPV-Al vs IPV were: 96.1% vs 100% (type 1); 100% vs 100% (type 2); and 99.2% vs 100% (type 3) respectively. IPV-Al was non-inferior to IPV, as the lower 95% confidence limits of the treatment differences were above the pre-defined -10%-point limit: 3.94% (-6.51; -2.01) for type 1; 0.0% (-1.30; -1.37) for type 2; -0.85 (-2.46; 0.40) for type 3. The booster effects for the group primed with IPV-Al versus the group primed with IPV were 25.3 vs 9.2 (type 1), 19.1 vs 6.5 (type 2) and 50.4 vs 12.5 (type 3). IPV-Al had a comparable safety profile to that of IPV. CONCLUSIONS: Non-inferiority of IPV-Al to standard IPV with respect to seroconversion after vaccination at 2, 4 and 6 months was confirmed for all three poliovirus serotypes. A robust booster response was demonstrated following vaccination with IPV-Al, regardless of the primary vaccine received. Both vaccines were well tolerated. ClinicalTrials.gov identifiers: NCT03025750 and NCT03671616. FUNDING: Bill & Melinda Gates Foundation.
引用
- Sáez-Llorens X, Thierry-Carstensen B, Stoey LS, et al. Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, following vaccination in children at 2, 4, 6 and at 15-18 months. Vaccine. 2020. PMID: 32273184. doi:10.1016/j.vaccine.2020.02.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。